Table 2 Antibodies and immunohistochemistry conditions.
From: Prognostic impact of tumor budding in endometrial carcinoma within distinct molecular subgroups
Target | Clone | Provider | Dilution | Pretreatment | Stainer |
|---|---|---|---|---|---|
p53 | Do-7 | Dako | 1:800 | EDTA at 95 °C for 20 min | Leica Bond |
MLH1 | M1 | Roche Diagnostics | Ready to use | EDTA at 100 °C for 32 min | Ventana Benchmark |
MSH2 | G219-1129 | Roche Diagnostics | Ready to use | EDTA at 100 °C for 40 min | Ventana Benchmark |
MSH6 | SP93 | Roche Diagnostics | Ready to use | EDTA at 100 °C for 64 min | Ventana Benchmark |
PMS2 | A16-4 | Roche Diagnostics | Ready to use | EDTA at 100 °C for 92 min | Ventana Benchmark |
